Navigation Links
Phase 3 Topical Drug for Raynaud's Disease Available for Licensing/Acquisition at the J.P. Morgan Conference
Date:12/13/2012

BOTHELL, Wash., Dec. 13, 2012 /PRNewswire-iReach/ -- MediQuest Therapeutics Inc., a specialty pharmaceutical company focused on inflammatory skin diseases and conditions, today announced that they will be conducting partnering/M&A meetings at the J.P. Morgan 31st Annual Healthcare Conference between January 7th and 10th in San Francisco, regarding its Phase 3 topical formulation, VASCANA, designed to treat Raynaud's Disease, an unmet medical need. MediQuest is also selling/licensing the remainder of its topical assets including a skin lightener, ready for commercialization.  Its topical/non-systemic Onychomycosis drug was out-licensed in August 2012.

(Photo: http://photos.prnewswire.com/prnh/20121213/CG29278)

MediQuest's VASCANA has a Special Protocol Assessment granted by the Federal Food & Drug Administration for a single Phase 3 study involving approximately 150 patients that suffer from moderate to severe symptoms of Raynaud's Syndrome.  VASCANA has a strong safety profile and an extensive intellectual property portfolio with issued patents that run to 2026.   The peak sales in the United States is estimated at about $250 million, as well as similar markets in EU and Asia, with low cost of goods, supported by 2-years of stability data.

Any company interested in learning more about VASCANA can arrange to meet with MediQuest at the J.P. Morgan conference through the below contact information.  

About Raynaud's Disease
An estimated 9-11 million people in the United States suffer from Raynaud's Disease, 2.1 million of which have been diagnosed and are seeking medical treatment. Raynaud's patients can experience severe pain associated with chronic vasospasm episodes in their hands, feet and other extremities.

About MediQuest Therapeutics, Inc.
MediQuest Therapeutics is a specialty pharmaceutical company using its proprie
'/>"/>

SOURCE MediQuest Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
2. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
3. Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
4. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
5. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
6. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
7. uniQure Initiates Phase I in Acute Intermittent Porphyria
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
10. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
11. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... COVENTRY, R.I. , May 22, 2015 /PRNewswire/ ... a once-daily central nervous system stimulant indicated for ... available to patients beginning Summer 2015. ... Aptensio XR received approval from the U.S. Food ... XR is an extended-release formulation of methylphenidate capsule ...
(Date:5/22/2015)... China , May 22, 2015  China Nepstar ... "Company"), a leading retail drugstore chain in ... operated stores, today announced the resignation of Mr. ... for personal reasons, effective immediately. Ms. Rebecca Yingnan ... by the Company,s board of directors, effective immediately. Meanwhile, ...
(Date:5/21/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/6csvbs/market_assessment ... "Market Assessment of Respiratory Diagnostics in the United ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service provides ... in the United States ... provides detailed analysis of the current and forecasted ...
Breaking Medicine Technology:Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 2China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 3United States and Europe Respiratory Diagnostics Market Assessment 2015 2
... Feb. 23, 2011 Competitive Intelligence (CI) groups ... navigate today,s volatile business environment. It is CI ... that set an organization,s strategic and tactical direction ... pharmaceutical industry, organizations need to have policies and ...
... INDIANAPOLIS and FORT BRAGG, N.C., Feb. 23, 2011 Roche ... received approval from the U.S. Department of Defense (DOD) to ... Womack Army Medical Center through the DOD,s secure B2B gateway. ... be approved by the DOD for this remote access. ...
Cached Medicine Technology:Reducing Risk and Ensuring Effectiveness in Competitive Intelligence Groups 2Roche Teams with Womack Army Medical Center to Become First IVD Manufacturer approved for Remote Network Connectivity with DOD 2
(Date:5/26/2015)... 2015 Beginning this fall, Boston University ... online Master of Social Work (MSW) program . Already ... Charles River Campus, the online option will be offered ... Standing option is open to applicants holding an undergraduate ... Work Education. Students entering the program will be granted ...
(Date:5/25/2015)... Dallas, TX (PRWEB) May 26, 2015 ... H1 2015” provides comprehensive information on the therapeutic ... pipelines by identifying new targets and MOAs to ... H1 2015 pipeline review of Liver Failure with ... across 65 pages is available at http://www.rnrmarketresearch.com/liver-failure-pipeline-review-h1-2015-market-report.html ...
(Date:5/25/2015)... NY (PRWEB) May 26, 2015 ... Laquanis Hooker as a 2015-2016 inductee into its VIP ... with this prestigious distinction for leadership in dentistry. NAPW ... women, boasting more than 700,000 members and over 200 ... Laquanis into this exceptional group of professional women,” said ...
(Date:5/25/2015)... 2015 World Patent Marketing, a vertically ... Big Little Party Table, a party invention that gives ... will suit their party needs. , "Worldwide indoor and ... this past year. Party Supply Rentals alone are ... Cooper, CEO and Creative Director of World Patent ...
(Date:5/25/2015)... 25, 2015 A recent report for ... persons have died as a direct result of an opiate ... a 33% rise in overdose deaths attributed to prescription opiate ... issue doesn’t care about geography. This issue doesn’t care about ... care about class.” As the state of Mass. reels from ...
Breaking Medicine News(10 mins):Health News:Boston University to Offer Online Master of Social Work Advanced Standing Option 2Health News:Boston University to Offer Online Master of Social Work Advanced Standing Option 3Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:National Association of Professional Women Inducts Dr. Laquinas Hooked, D.D.S. of General Dentist, Into its VIP Professional Woman of the Year Circle 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 3Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2
... On Wednesday, September 14, Allan Coukell, a pharmacist and ... will testify before the Senate Health Education Labor and ... ensure the safety of the U.S. drug supply. ... now originate outside the U.S. Increasingly, Americans rely ...
... , FRIDAY, Sept. 9 (HealthDay News) -- One-third of ... metabolic disorder, a new study finds. This disorder ... naturally from many foods -- that has a foul, fishy ... disease that impairs the ability of an enzyme to metabolize ...
... human papillomavirus (HPV) vaccine Cervarix may be just as effective ... measures against cervical cancer, according to a new study published ... Cancer Institute . Across the globe, cervical cancer is ... 16 and 18 are a large contributor to the development ...
... Jenifer Goodwin HealthDay Reporter , THURSDAY, Sept. 8 ... or the death of a child in infancy have an ... study suggests. Researchers from the United Kingdom looked at ... stillborn child between 1971 and 2006 or whose child died ...
... each year with stage III or,locally advanced ... a viable,treatment option. Optimizing nonsurgical treatment strategies ... In an article published online,September 8, 2011 ... Institute, RTOG,researchers report that treating patients with ...
... HealthDay Reporter , THURSDAY, Sept. 8 (HealthDay News) -- ... rise, reaching 22.6 million, or 8.9 percent of the population, ... has largely been driven by more marijuana use, according to ... fact, in 2010 some 17.4 million Americans were using marijuana, ...
Cached Medicine News:Health News:Fewer than 3 doses of cervical cancer vaccine effective 2Health News:Losing Child in First Year Might Raise Early Death Risk for Parent 2Health News:Losing Child in First Year Might Raise Early Death Risk for Parent 3Health News:Concurrent chemo and radiation therepy improves long-term survival for inoperable stage III lung cancer 2Health News:More U.S. Adults Using Illegal Drugs: Report 2Health News:More U.S. Adults Using Illegal Drugs: Report 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: